Cornelia de Lange syndrome Cornelia de Lange syndrome (CdLS) is a rare genetic disorder that presents with variable clinical abnormalities including
dysmorphic features, severe growth retardation,
global developmental delay, and
intellectual disability. The frequency varies from 1:10 000 to 1:30 000 live births without differences between ethnic groups. SMC1A is one of five genes that have been implicated in CdLS. Pathogenic variants in
SMC1A, missense and small in frame deletions, are associated with CdLS.
SMC1A variants, which maintain the frame of their encoded proteins, are associated with milder CdLS phenotypes with moderate neurocognitive disability and a paucity of major structural defects. The phenotype of
SMC1A affected males is more severe than that of mutated females. Since
SMC1A escapes X inactivation, it has been hypothesized that the mechanism in affected females is the dominant-negative effect of the mutated protein.
Genome instability and cancer SMC1A also takes part in DNA repair. The down-regulation of
SMC1A causes genome instability, and CdLS cells carrying
SMC1A variants display high level of chromosome aberrations. Furthermore, SMC1A is phosphorylated on Ser957 and Ser966 residues by ATM and ATR threonine/serine kinases following DNA damage induced by chemical treatment or ionizing radiation. It has been hypothesized that the Breast cancer type 1 susceptibility (BRCA1) gene collaborates in phosphorylating SMC1A, which is required for activation of the S-phase checkpoint allowing blocking of the cell cycle and the repair of DNA.
SMC1A plays a pivotal role in colorectal tumorigenesis. Indeed, colorectal tissue acquires extra-copies of
SMC1A during cancer development and its expression is significantly stronger in carcinomas than in normal mucosa and early adenoma. ==Notes==